{"id":"https://openalex.org/W4286296170","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.1529","title":"FDA analysis of expanded access use in pediatric patients from 2015 to 2020.","display_name":"FDA analysis of expanded access use in pediatric patients from 2015 to 2020.","alternate_titles":[],"publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4286296170","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.1529"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.1529","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.1529","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.1529","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4286296170"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024188757","display_name":"Elizabeth S. Duke","orcid":"https://orcid.org/0000-0002-3361-1436","observed_orcids":["https://orcid.org/0000-0002-3361-1436"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Duke","raw_affiliation_strings":["US Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031085992","display_name":"Natasha L. Kormanik","orcid":"https://orcid.org/0009-0006-5709-9429","observed_orcids":["https://orcid.org/0009-0006-5709-9429"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natasha L. Kormanik","raw_affiliation_strings":["U.S. Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"U.S. Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015176786","display_name":"Amy K. Barone","orcid":"https://orcid.org/0000-0002-5205-9544","observed_orcids":["https://orcid.org/0000-0002-5205-9544"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Barone","raw_affiliation_strings":["FDA, Washington, DC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"FDA, Washington, DC;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035436218","display_name":"Harpreet Singh","orcid":"https://orcid.org/0000-0003-1526-0916","observed_orcids":["https://orcid.org/0000-0003-1526-0916"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harpreet Singh","raw_affiliation_strings":["Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004000071","display_name":"Julia A. Beaver","orcid":"https://orcid.org/0000-0002-0725-2863","observed_orcids":["https://orcid.org/0000-0002-0725-2863"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia A. Beaver","raw_affiliation_strings":["U.S. Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"U.S. Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051520990","display_name":"Richard Pazdur","orcid":"https://orcid.org/0000-0002-4771-9923","observed_orcids":["https://orcid.org/0000-0002-4771-9923"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Pazdur","raw_affiliation_strings":["Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019914745","display_name":"Gregory H. Reaman","orcid":"https://orcid.org/0000-0002-6698-4503","observed_orcids":["https://orcid.org/0000-0002-6698-4503"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory H. Reaman","raw_affiliation_strings":["U.S. Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"U.S. Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065105775","display_name":"Martha Boeri Donoghue","orcid":"https://orcid.org/0000-0003-4493-6399","observed_orcids":["https://orcid.org/0000-0003-4493-6399"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martha Boeri Donoghue","raw_affiliation_strings":["Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD;","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"1529","last_page":"1529"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13417","display_name":"Biomedical Ethics and Regulation","score":0.7710000276565552,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T13417","display_name":"Biomedical Ethics and Regulation","score":0.7710000276565552,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.17599999904632568,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.0357000008225441,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/expanded-access","display_name":"compassionate use","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pediatric-cancer","display_name":"childhood cancer","score":0.9169999957084656},{"id":"https://openalex.org/keywords/investigational-drugs","display_name":"investigational drugs","score":0.6740000247955322},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8659999966621399},{"id":"https://openalex.org/keywords/central-nervous-system-tumors","display_name":"central nervous system tumors","score":0.9760000109672546},{"id":"https://openalex.org/keywords/drug-use-trends","display_name":"drug use trends","score":0.5609999895095825},{"id":"https://openalex.org/keywords/access-to-innovative-medicines","display_name":"access to innovative medicines","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9232087135314941},{"id":"https://openalex.org/C2775832928","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Expanded access","level":2,"score":0.5867300629615784},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5147092938423157},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.489729642868042},{"id":"https://openalex.org/C2780084366","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demographics","level":2,"score":0.4536844491958618},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.41290557384490967},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3703112006187439},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.3281264901161194},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31823456287384033},{"id":"https://openalex.org/C149923435","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demography","level":1,"score":0.1311514675617218},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.1529","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.1529","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.1529","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2930750125","https://openalex.org/W3047302402","https://openalex.org/W3030163245","https://openalex.org/W2891502398","https://openalex.org/W4380151383","https://openalex.org/W2947607219","https://openalex.org/W2807780552","https://openalex.org/W4281627375","https://openalex.org/W2556422387","https://openalex.org/W4379285837"],"abstract_inverted_index":{"1529":[0],"Background:":[1],"Expanded":[2],"Access":[3],"is":[4,310],"a":[5,12,27],"regulatory":[6],"mechanism":[7],"that":[8,116],"enables":[9],"patients":[10,142],"with":[11,21,44,206],"life-threatening":[13],"condition":[14],"or":[15,33,100,125,252],"serious":[16],"disease":[17],"to":[18,74,161,208,239,315,326],"receive":[19],"treatment":[20],"an":[22],"investigational":[23,68],"drug":[24,70,94,233],"outside":[25],"of":[26,42,77,147,179,200,267,277,289,292,305,350],"clinical":[28],"trial":[29],"when":[30],"no":[31],"comparable":[32],"satisfactory":[34],"alternative":[35],"options":[36],"are":[37,282,313],"available.":[38],"FDA":[39,238],"has":[40,49],"decades":[41],"experience":[43],"expanded":[45],"access,":[46],"but":[47],"little":[48],"been":[50],"reported":[51,165],"about":[52],"its":[53,317,324],"use":[54],"in":[55,120,166,171,284,342,354],"pediatric":[56,150,301,339],"cancer":[57],"patients.":[58,302],"Methods:":[59],"FDA\u2019s":[60],"central":[61],"electronic":[62],"database":[63],"was":[64,152,241,246],"queried":[65],"for":[66,114,141,211,217,222,229,237,248,300,308],"single-patient":[67],"new":[69,352],"(spIND)":[71],"applications":[72],"submitted":[73],"the":[75,106,192,227,262,268,295,338],"Office":[76],"Oncologic":[78],"Diseases":[79],"between":[80],"January":[81],"2015":[82],"through":[83],"December":[84],"2020.":[85],"Data":[86],"collection":[87],"included":[88],"IND":[89,92],"receipt":[90],"date,":[91],"type/status,":[93],"name,":[95],"and":[96,111,226,231,322,329],"patient":[97,128,320],"demographics.":[98],"Duplicate":[99],"exempt":[101],"INDs,":[102],"those":[103,112],"cancelled":[104],"by":[105,271],"physician-sponsor":[107],"before":[108],"initiating":[109],"therapy,":[110],"requested":[113],"indications":[115],"occur":[117],"almost":[118],"exclusively":[119],"adults":[121],"(e.g.":[122],"lung":[123],"cancer)":[124],"were":[126,130,140,164,169,181,191,204,216,256,299],"missing":[127],"age":[129,156],"excluded.":[131],"Results:":[132],"Of":[133],"2,901":[134],"unique":[135,202],"spINDs":[136,210,293],"granted,":[137],"534":[138],"(18%)":[139],"less":[143],"than":[144],"18":[145],"years":[146,158,288,298],"age.":[148],"The":[149],"population":[151],"57%":[153],"male,":[154],"median":[155],"6.0":[157],"(range":[159],"0.1":[160],"17);":[162],"race/ethnicity":[163],"<1%.":[167],"Patients":[168],"treated":[170],"132":[172],"zip":[173],"codes":[174],"across":[175],"39":[176],"states;":[177],"one-quarter":[178],"submissions":[180],"from":[182],"5":[183],"large":[184],"academic":[185],"hospitals.":[186],"Central":[187],"nervous":[188],"system":[189],"tumors":[190],"most":[193],"common":[194],"indication":[195],"(Table":[196],"1).":[197],"A":[198],"total":[199],"98":[201],"drugs":[203,353],"requested,":[205],"1":[207,242,259],"73":[209],"each":[212],"drug;":[213],"approximately":[214,275],"50%":[215],"tyrosine":[218],"kinase":[219],"inhibitors,":[220],"25%":[221],"other":[223,232],"small":[224],"molecules,":[225],"remainder":[228],"immunotherapies":[230],"types.":[234],"Median":[235],"time":[236],"grant":[240],"day.":[243],"Follow-up":[244],"information":[245],"provided":[247],"75%":[249],"(annual":[250],"report":[251],"withdrawal":[253],"letter);":[254],"1/3":[255],"withdrawn":[257],"within":[258,337],"year.":[260],"Over":[261],"last":[263,296],"2":[264],"years,":[265],"utilization":[266,304],"program":[269,307],"increased":[270],"120%.":[272],"Conclusions:":[273],"While":[274],"1%":[276],"all":[278],"cancers":[279],"per":[280],"year":[281],"diagnosed":[283],"children":[285,309],"under":[286],"17":[287],"age,":[290],"18%":[291],"over":[294],"five":[297],"Although":[303],"this":[306],"robust,":[311],"efforts":[312],"needed":[314],"assess":[316],"impact":[318],"on":[319],"outcomes":[321],"ensure":[323],"availability":[325],"patients,":[327],"families,":[328],"institutions":[330],"more":[331],"widely.":[332],"These":[333],"data":[334],"highlight":[335],"interest":[336],"oncology":[340],"community":[341],"accessing":[343],"innovative":[344],"therapies,":[345],"which":[346],"supports":[347],"early":[348],"investigation":[349],"promising":[351],"children.[Table:":[355],"see":[356],"text]":[357]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4286296170","counts_by_year":[{"year":2025,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-07-21T00:00:00"}
